ORIC Pharmaceuticals will advance its prostate cancer drug to Phase III trials after it showed survival benefit in a Phase Ib study. The Himalayas-1 trial will evaluate rinzimetos ...

编者按：2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO-GU）盛大召开，前列腺癌领域迎来术语体系革新、多项重磅研究数据更新与治疗格局的迭代升级。会议期间，肿瘤瞭望-泌尿时讯特邀美国威尔康奈尔医学院Scott T. Tagawa教授，围绕本届大会前列腺癌领域进展及精准治疗的未来方向，展开深度解读。 01 2026年ASCO GU研讨会汇聚了全球专家，共同分享泌尿生殖系统肿瘤领域的突破性研 ...

Investigators expanded on previous results from the DEAR study, comparing darolutamide versus enzalutamide and apalutamide ...